Sex-specific differences in the epidemiology, pathophysiology, presentation, and prognosis of atrial fibrillation (AF) have been well-described in this journal 1 . Despite a lower prevalence of AF in women than in men worldwide 2 , women generally experience worse symptoms and quality of life, and have a higher risk of stroke and death than men with AF 1, 3 . Thromboembolic stroke owing to AF accounts for approximately one-fifth of ischaemic strokes 4 , and one-quarter of all strokes in adults aged >80 years 5 . AF-related stroke is associated with severe outcomes, including 30-day mortality of 24-33% 4, 6, 7 . Female sex is a well-recognized independent risk factor for AF-related stroke. Among patients who have experienced a stroke, AF is more common in women than in men 8, 9 . Women are older at the time of stroke 10-12 and have a higher incidence of stroke when aged >75 years 10 . Moreover, compared with men, women are significantly more likely to be living alone or widowed before a stroke 12 , and suffer from greater neurological deficits after a stroke 13 . Therefore, improving stroke prevention in women with AF is critical to reducing the public-health burden of AF.
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In this Review, we describe sex-specific differences in the two major components of AF management: rate or rhythm control and stroke prevention (FIG. 1) . We describe differences in treatment utilization in AF between women and men, and evaluate potential sex-specific disparities or biases in health-care use. In addition, we assess sex-specific differences in enrolment, treatment efficacy, and treatment complications reported in randomized, controlled trials (RCTs) of AF. Finally, we identify potential barriers to effective treatment of AF in women that need to be addressed in the future.
Evaluating sex-specific differences Differences, disparities, and biases Sex-specific differences in health-care utilization in cardio vascular treatments are well-documented [14] [15] [16] . However, a systematic approach to examining sexspecific differences in AF treatment has been lacking. In our critical evaluation of studies that report sexspecific differences in the treatment of AF, we apply a three-tiered framework on differences, disparities, and biases proposed by Rathore and Krumholz
(FIG. 2).
For a sex-specific difference to be considered a disparity, the difference must be associ ated with worse clinical outcomes and cannot simply be a reflection of patientrelated factors. For instance, it might be inappropriate to invoke a health-care disparity if women with AF do not receive a treatment because of differential eligibility, contraindications to treatment, patient preferences, or confounding owing to demographic and medical character istics. However, overly stringent enrolment criteria in clinical trials might enhance trials' internal validity, but inadvertently reduce the studies' generalizability 18 . Establishing a health-care disparity implies that there are systemic factors associated with differences in treatment causing worse outcomes in one group compared with another. When sex-specific disparities are not caused by systemic health-care factors, they can indicate inherent unconscious biases in individual prov iders or the health-care system leading to lower quality of care. Whereas sex-related unconscious bias and stereo typing have been well-documented in health care 16, 19, 20 and academic science [21] [22] [23] , whether such biases occur in AF care has been inadequately studied. In subsequent discussions, we delineate challenges in establishing disparities or biases in sex-specific differences related to AF treatment.
Randomized clinical trials
We present sex-specific differences in treatment efficacy and safety using results derived from subgroup and post-hoc analyses of RCTs. Although subgroup and post-hoc analyses are often the main source for sexspecific data, they have a higher likelihood of producing false-positive results compared with prespecified analyses. In addition, many RCTs were not powered to study sex-specific differences in primary or secondary outcomes, which might contribute to false-negative findings. Our ability to derive sex-specific results is further limited by underrepresentation of women in cardiovascular disease prevention trials 24 . Only 25-30% of the participants in the major trials of warfarin were women (FIG. 3) . The proportion of female participants has increased in trials of the non-vitamin K antagonist oral anticoagulants (NOACs) to approximately 40%, to reflect more accurately the relative prevalence of AF in women compared with men. Despite the described limitations, our aim is to emphasize the importance of sex-specific differences in treatment outcomes in RCTs in order to provide evidence-based management for all patients and to highlight potential differences in response to treatment between women and men for further investigation.
Rate and rhythm control
There have been limited studies to investigate sexspecific outcomes and complications with rate-control and rhythm-control strategies. We focus our discussion on the most clinically salient topics relevant to sex-specific differences, and provide critical evaluation of RCTs (details of individual trials are listed in TABLE 1) and large observational studies available to date. For a comprehensive list of the observational studies, see Supplementary information S1 (table) .
The AHA/ACC/HRS 25 and the ESC 26 guidelines recommend both pharmacological control of ventricular rate and pharmacological and electrical cardioversion as first-line therapy for all types of AF (class I). Several RCTs to evaluate rate versus rhythm control have demonstrated no significant differences in clinical outcomes between the two treatment strategies [27] [28] [29] [30] . However, US guidelines suggest that earlier restoration of sinus rhythm can slow progression of AF and reduce morbidity 25 .
Utilization
Data from the Euro Heart Survey 31 showed that, in an unadjusted analysis of patients with typical symptoms, there was no sex-specific difference in the use of rate versus rhythm control, whereas in patients with atypical or no symptoms, women were more likely to receive rate over rhythm control compared with men. In comparison, the Euro Observational Programme Pilot survey on AF 32 reported that, in an unadjusted analysis among patients with typical symptoms, women were more likely to receive rate over rhythm control than men, and there was no sex-specific difference in treatment for asymptomatic patients. The survey also reported that men were more likely to have asymptomatic AF than women 33 . Neither of the studies adjusted for important
Key points
• Evaluation of sex-specific differences, disparity, and bias in health-care utilization requires presence of adverse outcomes and investigation into treatment eligibility, contraindications to treatment, patient preferences, and confounding owing to patient characteristics • Women are less likely to undergo rhythm-control treatment than men; among individuals undergoing rhythm-control treatment, women are less likely to receive electrical cardioversion and catheter ablation than men • No significant differences exist in the use of oral anticoagulants between women and men; however, among individuals receiving dabigatran, women are more likely to receive the lower dose than men • Warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) have similar efficacy in women and men; however, among individuals receiving warfarin, women might have higher residual risk of stroke or systemic embolism • Warfarin and NOACs have similar bleeding risks in women and men • Future studies need to examine patient, provider, and health-system factors to address whether disparities or bias contribute to sex-specific differences in utilization and outcomes of treatments for atrial fibrillation 34 . However, given the lack of adjustment for duration and burden of AF, symptoms, and left atrial enlargement, it remains unclear whether there is a true sex-specific disparity in utilization of rate versus rhythm control in clinical practice. Sex and age effects on the pharmacology of available agents to treat AF, as well as patient preferences might influence the choice between rate-control and rhythm-control therapy; however, these topics have not currently been addressed adequately in the literature.
Outcomes
Sex-specific differences in outcomes of rate versus rhythm control were investigated in subgroup analyses of the AFFIRM and RACE trials. In the AFFIRM trial 27 , the risk of death did not differ by sex between rate-control and rhythm-control strategies. In comparison, the RACE trial 28 reported that women treated with rhythm control had a higher incidence of the primary end point (composite of cardiovascular mortality, heart failure, thromboembolic complications, adverse effects of antiarrhythmic drugs, and pacemaker implantation) compared with women treated with rate control (32.0% versus 10.5%; absolute difference 21.5%, 90% CI 12.1-30.8%). In men, the incidence of the primary end point did not differ significantly between the two treatment groups (17.2% versus 21.1%; absolute difference −3.9%, 90% CI −11.1% to 3.2%). Interpretation and clinical translation of the sex-specific analysis of the RACE trial are challenging because of the small sample size and the use of a composite end point consist ing of a wide range of outcomes without reporting the individual event rates.
Cardioversion
In patients with no contraindications, the AHA/ACC/ HRS and ESC guidelines recommend amio darone, dofetilide, flecainide, intravenous ibutilide, and propafenone for pharmacological cardioversion 25, 26 . There have been no consistent reports of sex-specific differences in the type of antiarrhythmic drug used in observational studies 31, 32 . Likewise, no sex-specific differences in likelihood of sinus rhythm have been shown with the use of antiarrhythmics 35 . Some studies have reported that rhythm-control medications increased the risk of torsades de pointes 36, 37 and sick sinus syndrome in women compared with men 38 . A few unadjusted analyses from observational studies have reported that electrical cardioversion is less common in women than in men 31, 32, 39 . Without a critical evalu ation of confounders associated with use of electrical cardioversion and in the absence of established superiority of cardioversion to rate control, we cannot establish disparities in the use of cardioversion in the treatment of AF. Electrical cardioversion is generally associated with similar success rates in women and men [39] [40] [41] , although one study suggested after multivariable adjustments that the risk of AF recurrence was higher in women than in men 42 .
Catheter ablation
Catheter ablation is currently recommended as a treatment for patients with symptomatic AF that is uncontrolled by antiarrhythmic drugs or for those who cannot tolerate pharmacological treatments (class I for paroxysmal AF, class IIa for persistent AF, class IIb for >12 months of persistent AF) 25, 43 . Selection of appro priate patients is a complex process that requires careful consideration of clinical factors including symptoms, presence of heart disease, obesity, sleep apnoea, left atrial size, duration of persistent AF, and patient preferences 43 . A few large administrative regis tries have reported that, after multivariable adjustments, women are less likely to undergo catheter ablation than men 34, 44 , and that women are under represented in catheter ablation meta-analyses [45] [46] [47] [48] . A review on the association between sex and outcomes of catheter ablation for AF has also reported that women are referred less often and later than men 49 . However, the differences in utilization of catheter ablation between women and men might be secondary to sex-specific differences in clinical factors, and not primarily associated with female sex per se. Moreover, sex-specific differences in ablation utilization might represent less willingness by women to undergo invasive cardiovascular procedures compared with men, similar to earlier studies on the use of coronary angiography for myocardial infarction [50] [51] [52] [53] . In observational settings, the risk of long-term recurrence of AF after catheter ablation seems to be similar between women and men after adjusting for age, left atrial size, and proportion of paroxysmal AF 47 . One meta-analysis reported higher recurrence rates among women; however, the researchers acknowledged a higher mean age in the women than in the men 46 . Important procedural complications of catheter ablation include vascular injury, pericardial effusion or tamponade, pulmonary vein stenosis, oesoph ageal injury, stroke, and systemic thromboembolism 45 . Several studies have attempted to address potential sex-specific differences in the rates of complications after catheter ablation, but have produced inconsistent results; some studies showed no significant difference [54] [55] [56] , whereas others reported female sex to be a predictor of higher complication rates [57] [58] [59] [60] [61] [62] . In one of the larger studies, Medicare beneficiaries displayed no sex-specific differences in 30-day stroke or mortality outcomes, but women were more likely to develop peri cardial effusions after the procedure 61 . Interpretation of the results is limited owing to low event rates, compounded by the relative lack of representation of women and the use of composite end points. In addition, the biological underpinnings of the reported sex-specific differences remain largely unknown.
Stroke prevention
Untreated AF is associated with a threefold to fivefold increased risk of stroke 5 . AF-related stroke is often severe; 24-33% of individuals with stroke in the setting of AF die within 30 days, and an additional 35% lose their ability to live independently 6, 7, 63 . Oral anticoagulation therapy with warfarin reduces the risk of stroke by 64% compared with placebo, and by 39% compared with aspirin 64 . NOACs are as effective as warfarin and have improved safety profiles. The AHA/ACC/HRS 25 and ESC 26 guidelines currently recommend anticoagulation in individuals with a CHA 2 DS 2 -VASc score of 2 or 1, respectively. A percutaneous left atrial appendage closure device (WATCHMAN; Boston Scientific, USA) was approved by the FDA in 2015 as an additional strategy for stroke prevention in AF 65 .
Oral anticoagulant prescription
Investigators from GARFIELD-AF registry have reported that the overall rate of anticoagulant use (vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors, unfractionated or low-molecular-weight heparin) did not differ between women (60.8%) and men (60.9%) 66 . There were no sex-specific differences in the rates of anticoagulant use among those with a CHADS 2 score ≥2; both undertreatment and overtreatment were common regardless of sex. By contrast, among the patients with a CHA 2 DS 2 -VASc score ≥2 enrolled in the PINNACLE registry, women were more likely than men to receive aspirin instead of oral anticoagulants (OACs) after multivariable adjustments (relative prescription rate of aspirin instead of OAC for men 0.91, 95% CI 0.90-0.92, P <0.001) 67 .
A few observational studies have investigated utilization of NOACs in clinical practice. In the GARFIELD-AF registry, 11.8% of men and 11.7% of women received factor Xa inhibitors or direct thrombin inhibitors 66 . Data from Get With The GuidelinesStroke showed no difference in the discharge prescription of dabigatran or rivaroxaban versus warfarin between women and men hospitalized for AF-related stroke or transient ischaemic attack during 2010-2012 (REF. 68 ). On the contrary, among the 18,611 OACnaive patients with AF in a Danish registry, men were less likely than women to be started on apixaban, dabigatran, or rivaroxaban, versus warfarin during 2011-2013 (multivariable-adjusted male sex OR 0.88, 95% CI 0.83-0.94, P <0.001) 69 . Reasons for the variation by sex are unclear, but might represent residual confounding owing to sex-specific differences in baseline comorbidities (see Supplementary information S2 (table) ).
A population-based cohort study from Quebec, Canada reported that women were more likely than men to be prescribed the lower dose of dabigatran (110 mg), even after adjustment for age and baseline comorbidities associated with CHA 2 DS 2 -VASc and HAS-BLED scores (multivariable-adjusted OR 1.35, 95% CI 1.24-1.48) 70 . Both younger (age <75 years) and older (age ≥75 years) women were also more likely than men to receive the lower dose (22.8% versus 18.5%, and 83.5% versus 76.0%; P <0.05 for both age groups). The finding remains to be replicated, and it is unclear whether these results indicate a disparity in the way clinicians assess the risk of stroke or bleeding in women compared with men. The finding that women are more likely than men to receive the lower dose of dabigatran, when the higher dose (150 mg) has been demonstrated to be superior to warfarin in prevention of stroke and systemic embolism 71 , warrants further investigation.
Warfarin
The AHA guidelines currently recommend warfarin with well-controlled international normalized ratio (INR) as a class I indication for stroke prevention in nonvalvular AF 72 . Owing to decades of experience with the drug and its cost-efficiency, particularly in lowincome and middle-income countries, anticoagulation with warfarin remains the most widely used stroke prevention therapy in AF worldwide. The main sex-specific findings on the efficacy and bleeding complications of warfarin are discussed below. For detailed results, see Supplementary information S3,S4 (tables). Efficacy compared with placebo. Sex-specific differences in the efficacy of warfarin compared with placebo in the prevention of stroke or systemic embolism were investigated in a meta-analysis of five RCTs (AFASAK, CAFA, BAATAF, SPAF, and SPINAF studies; TABLE 1). Warfarin was found to reduce the risk of stroke by 84% (95% CI 55-95%, P <0.001) in women and 60% (95% CI 3-68%, P = 0.04) in men 73 . No formal test for interaction between sex and efficacy was performed, and the confidence intervals overlapped. In addition, the meta-analysis incorporated a male-only study (SPINAF) and combined results from trials with different target INRs, further limiting our ability to draw sex-specific conclusions.
Residual risk of stroke or systemic embolism. A few studies have reported that women treated with warfarin have a higher residual risk of stroke or systemic embolism than men. In a meta-analysis of the warfarintreatment groups of the ARISTOTLE, BAFTA, RE-LY, ROCKET AF, and SPORTIF III and V trials, women had a significantly higher residual risk of stroke and systemic thromboembolism than men (OR 1.28, 95% CI 1.11-1.47, P = 0.001) 74 . Also, in a post-hoc analysis of the AFFIRM trial, among individuals receiving warfarin, women had an increased residual risk of ischaemic stroke compared with men even after adjusting for percentage time in therapeutic range (TTR; multivariable-adjusted HR 1.54, 95% CI 1.10-2.16, P = 0.01) 75 .
Risk of bleeding.
Potential sex-specific differences in the risk of major bleeding among warfarin users were investigated in post-hoc analyses of the SPORTIF III and V trials. In a combined analysis of the participants randomly assigned to warfarin treatment, no significant difference was found in the risk of major bleeding between women and men 76 . In the meta-analysis of the ARISTOTLE, BAFTA, RE-LY, ROCKET AF, and SPORTIF III and V trials, the risk of major bleeding was similar in women and men among the participants receiving warfarin 74 81, 82 , and an INR >3.5-4.0 increases the risk of bleeding 83, 84 . TTR is closely associated with the risk of stroke, bleeding, and mortality 85, 86 , and has been used as a marker for quality of anticoagulation therapy. Various factors including age, female sex, lower income, black ethni city, chronic diseases, cognitive impairment, poly pharmacy, INR target range, setting of anticoagu lation care, and patient adherence have been associated with lower TTR [87] [88] [89] . The SAMe-TT 2 R 2 score, a risk-assessment tool includes female sex as one of the predictors of low TTR 90, 91 . The higher residual stroke risk in warfarin-treated women compared with men has been suggested to be partly owing to reduced TTR in women. Among the warfarin users in the AFFIRM trial 75 , women were more likely than men to have an INR <2 (29 ± 0.7% versus 26 ± 0.5%; P = 0.0002). Women were also reported to spend a higher percentage of time outside the therapeutic range (40 ± 0.7% versus 37 ± 0.5%; P = 0.0001) compared with men. Similarly, in the RE-LY trial 92 , male sex was associated with increased TTR in multivariable analysis (1.37% increase in mean TTR, 95% CI 0.30-2.45, P = 0.01).
Data from observational studies have been inconsistent; some studies report lower TTR in women [93] [94] [95] , whereas others report no sex-specific differences in TTR 11, [96] [97] [98] [99] [100] . In addition, sex has not been consistently associated with INR stability in longitudinal studies 101, 102 .
NOACs
To date, four NOACs have been approved by the FDA and European Medicines Agency for stroke prevention in nonvalvular AF -the direct thrombin inhibitor dabigatran, and the factor Xa inhib itors apixaban, edoxaban, and rivaroxaban. With the exception of edoxaban, which was approved in 2015, NOACs have been recommended by both the Canadian Cardiovascular Society 103 and the ESC 26 as the preferred agents over warfarin for stroke prevention in non valvular AF. The AHA recommends 69, [107] [108] [109] . Major sex-specific data from the NOAC trials are discussed below, and see Supplementary information S5 (table) .
Efficacy compared with warfarin.
A meta-analysis of the ARISTOTLE (apixaban 5 mg twice daily), ENGAGE AF-TIMI 48 (edoxaban 60 mg once daily), RE-LY (dabiga tran 150 mg twice daily), and ROCKET AF (rivaroxa ban 20 mg once daily) trials showed no sexspecific differences in the efficacy of stroke prevention between NOACs and warfarin (relative risk for NOACs versus warfarin in women 0.78, 95% CI 0.65-0.94, and in men 0.84, 95% CI 0.75-0.94, P = 0.52 for inter action) 110 . Sex-specific subgroup analy ses of the individual RCTs for each drug reported simi lar find ings 71, 104, 105, 111 , as did post-hoc analyses of the ARISTOTLE 112 and AVERROES 113 trials.
Residual risk of stroke or systemic embolism.
A meta-analysis of the participants randomly assigned to receive a NOAC in the AVERROES, ARISTOTLE, RE-LY (150 mg dose), and ROCKET AF trials reported similar rates of all stroke or systemic embolism in women and men (OR 1.15, 95% CI 0.97-1.35, P = 0.11) 74 . A post-hoc analysis of the AVERROES trial 113 showed that, in the apixaban group, women had higher risk of ischaemic stroke than men, but no significant difference was found after multivariable adjustments. In addition, in combined analysis of the apixaban and warfarin groups of the ARISTOTLE trial 112 , no significant difference was found in the rate of stroke or systemic embolism between women and men after multivariable adjustments.
Relative risk of bleeding compared with warfarin.
A meta-analysis of the ARISTOTLE, ENGAGE AF-TIMI 48 (60 mg dose), and ROCKET AF trials reported no significant sex-specific difference in the rela tive risk of major bleeding when comparing factor Xa inhibitors to warfarin (relative risk for factor Xa inhibitors versus warfarin in women 0.75, 95% CI 0.58-0.97, and in men 0.90, 95% CI 0.72-1.12, P = 0.29 for interaction) 110 . Likewise, subgroup analyses in the individual trials demonstrated that, compared with warfarin, apixaban 104 and both doses of edoxaban 106 reduced the risk of major bleeding similarly for both women and men. The only trial that reported an interaction by sex for risk of bleeding was the ROCKET AF study 105 , in which rivaroxaban increased the risk of major and nonmajor clinically relevant bleeding compared with warfarin in men (HR 1.12, 95% CI 1.02-1.22), but not in women (HR 0.89, 95% CI 0.79-1.01, P = 0.004 for interaction).
Female sex and risk of bleeding. Several studies have investigated female sex as a prognostic factor for bleeding among users of OACs. A meta-analysis of the ARISTOTLE, AVERROES, RE-LY (150 mg dose), and ROCKET AF trials reported that women treated with NOACs had lower rates of major bleeding compared with men (OR 0.84, 95% CI 0.75-0.96, P = 0.007) 74 . Women receiving rivaroxaban or warfarin in the ROCKET AF trial 114 had a reduced risk of major bleeding compared with men after multivari able adjustment (HR 0.82, 95% CI 0.70-0.95, P = 0.009).
Similarly, in patients treated with apixaban or warfarin in the ARISTOTLE trial 115 , female sex was associated with a lower risk of major bleeding (HR 0.74, 95% CI 0.63-0.87, P = 0.002). Another post-hoc analysis of the ARISTOTLE trial 112 suggested a trend for lower risk of major bleeding in women compared with men (HR 0.86, 95% CI 0.74-1.01), although the result was not significant.
Left atrial appendage closure
Since its approval by the FDA in 2015, percutaneous left atrial appendage closure (using the Watchman device) has been available as a stroke-prevention strategy. The ESC currently recommends percutaneous left atrial appendage closure only for individuals with a high risk of stroke and contraindication to anticoagulation therapy (class IIb) 26 , whereas the AHA does not give a class recommendation for percutaneous left atrial appendage closure as a stroke-prevention strategy 25 . The PROTECT AF trial 116 showed that the Watchman device was noninferior to warfarin for the prevention of stroke, systemic embolism, and death (rate ratio [RR] 0.62, 95% CI 0.35-1.25), but the rate of adverse events was higher (RR 1.69, 95% CI 1.01-3.19). 
Rate and rhythm control
Sex-specific differences in rhythm-control strategy
• Identify mechanisms explaining sex-specific differences in outcomes associated with rhythm-control strategy including possible differences in complications after catheter ablation Sex-specific differences in resource utilization
• Determine patient, clinician, and system factors behind lower utilization of procedures among women, despite similar outcomes in women and men Risk-benefit evaluation • Identify sex-specific predictors of outcomes including genetics and biomarkers
Stroke prevention

Undertreatment in women
• Identify barriers to guideline-recommended oral anticoagulation • Identify reasons why women are more likely than men to receive aspirin than oral anticoagulation • Identify reasons why women are more likely than men to receive lower dose of dabigatran Sex-specific differences in stroke and bleeding risks • Achieve better understanding of stroke and bleeding risk under contemporary medication schemes
Effects of cardiovascular drugs
Sex-specific differences in pharmacokinetics and pharmacodynamics
• Identify mechanisms explaining sex-specific differences in pharmacokinetics of β-blockers • Investigate mechanisms for increased risk of complications from antiarrhythmic drugs in women • Identify mechanisms explaining sex-specific differences in pharmacokinetics and pharmacodynamics of warfarin
Lack of sex-specific evidence in trials
Sex-specific differences in trial participation
• Identify potential barriers to participation of women including exclusions and screening bias
Reporting of sex-specific results in trials
• Collect sex-specific information • Prespecify analyses of sex-specific results, and formally test for effect modification by sex
Differences versus disparities versus bias
When sex-specific differences in AF treatment, utilization, or outcomes are demonstrated, examine underlying factors
• Examine patient, clinician, and system factors including eligibility, contraindications, patient preferences, confounding, and role of stereotypes and unconscious biases Sex-specific subgroup analysis for efficacy showed inconsistent results (women RR 1.47, 95% CI 0.52-4.11; men RR 0.32, 95% CI 0.13-0.77), most likely owing to a lack of power with inclusion of only 210 women (30% of the total study population).
Pharmacological mechanisms
As noted in a 2015 statement from the ESC 117 , there are important sex-specific differences in the pharmacodynamics and pharmacokinetics of cardiovascular drugs. Important distinctions exist in absorption, body composition, distribution, and excretion of drugs between women and men. In addition, differences in endogenous and exogenous sex hormones might have an important role. Although sex-specific differences in the pharmacology of AF treatment drugs are likely, how they contribute to sex-related variation in the efficacy and safety of AF medications is uncertain.
In the RACE study 38 , no significant sex-specific difference in heart-rate response to treatment was noted. However, in the study of pharmacokinetics, women had higher plasma concentrations of β-blockers [118] [119] [120] [121] and possibly also of verapamil [122] [123] [124] than men. The differences in concentrations seemed to be related to differences in activity of drug-metabolism pathways and gastrointestinal absorption. Women also seemed to have increased cardiac noradrenaline activation compared with men 125 , which might partially explain why there was a similar heart-rate response despite higher concentrations of atrioventricular nodal-blocking agents 38 . Women treated with warfarin spend more time outside the therapeutic range compared with men, but the underlying mechanisms are unknown. The pharmaco kinetics and pharmacodynamics of warfarin are complex, and might vary by sex. In a large, prospective cohort study of 4,616 patients from >100 anticoagulation clinics across the USA, women required 4.5 mg (95% CI 3.8-5.3 mg, P <0.001) less in total weekly warfarin dose than men at any given age, and women aged ≥80 years required the lowest total weekly dose 126 . Lower mean body mass or hepatic fat content in women 126 and sex-specific differences in warfarin metabolism by cytochrome P450 owing to differences in sex hormones might partially account for the enhanced dose response to warfarin in women 127, 128 . Whether sex-specific differences in pharmacokinetics are translated to sex-related differences in INR stability needs further investigation.
Future directions
Potential future directions and research strategies for evaluating sex-specific differences in the treatment of AF are outlined in TABLE 2. Strategies to produce high-quality evidence for women require reporting sex-specific results in RCTs 24 . Although the best-quality sex-specific data would come from RCTs adequately powered to test independent effects in women and men, the design of such trials will be resource intensive. Nevertheless, increasing female participation in RCTs to reflect the current prevalence of disease will improve the generalizability of the trials. Identification of potential barriers to female participation in AF stroke prevention trials might facilitate their participation in future studies. Women with AF might be less eligible for these trials owing to their older age and lower renal function; nevertheless, there might be misperceptions in the assessment of bleeding risk in women versus men, which might affect screening of women for inclusion in the trials. Moreover, social or medical factors might further discourage participation by women 24 . A multicentre RCT that was designed to investigate sex-specific differences in participation in cardiovascular disease prevention trials reported that women showed less willing ness to participate, after adjusting for cardiovascular comorbidities, and greater perception of harm from participating in trials compared with men 129 . Pragmatic randomized trials, which maintain internal validity of experimental trials, but include lessstringent inclusion and exclusion criteria, might improve the generalizability of experimental trials. Enrolling women and patients underrepresented in standard clinical trials will help to determine effectiveness and safety of treatments for AF in real-world clinical practice 130 . Investigations into the ethnic disparities in care in patients with AF have revealed unconscious racial biases and a lack of knowledge of racial disparities in the risk of stroke in AF 131 . Factors influencing variation in utilization and outcomes in AF treatments by sex, including patient preferences and comorbidities versus disparities and unconscious biases require further investigation. Continued investigation into sex-specific differences in utilization, effectiveness, and complications of different treatment modalities will help to identify and address potential barriers to effective treatment in women.
Conclusions
The evidence for sex-specific differences in the utilization and outcomes of treatments for AF is accumulating. Understanding the underlying biological and sociocultural mechanisms for the sex-specific differences and identifying potential barriers to effective treatment in AF will help to reduce the public-health burden of AF. Ensuring adequate enrolment of women in clinical trials of AF and a priori specified secondary analyses of efficacy and complications of therapies by sex are essential to develop an adequate evidence base to manage women with AF.
